Suzanne R.L. Young

739 total citations
20 papers, 455 citations indexed

About

Suzanne R.L. Young is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Suzanne R.L. Young has authored 20 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Suzanne R.L. Young's work include Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (5 papers) and Estrogen and related hormone effects (4 papers). Suzanne R.L. Young is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (5 papers) and Estrogen and related hormone effects (4 papers). Suzanne R.L. Young collaborates with scholars based in United States, Spain and Italy. Suzanne R.L. Young's co-authors include David G. Skalnik, Fredrick M. Pavalko, Kenneth P. Nephew, Curtis Balch, Pearlly S. Yan, Teresa Craft, Tim H-M. Huang, Rita Gerard-O’Riley, Diana L. Carlone and Jill Sergesketter Butler and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Suzanne R.L. Young

19 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne R.L. Young United States	13	301	137	93	66	62	20	455
Sanja Šale United States	8	350 1.2×	231 1.7×	52 0.6×	62 0.9×	73 1.2×	9	516
Nicholas Jette Canada	6	448 1.5×	301 2.2×	58 0.6×	76 1.2×	44 0.7×	8	541
Dao Doan United States	7	250 0.8×	179 1.3×	71 0.8×	67 1.0×	30 0.5×	11	437
Tracy L. Krebs United States	6	267 0.9×	110 0.8×	82 0.9×	58 0.9×	23 0.4×	10	364
Jingxin Feng China	8	459 1.5×	198 1.4×	96 1.0×	184 2.8×	61 1.0×	13	604
Yi Hong China	13	217 0.7×	101 0.7×	55 0.6×	42 0.6×	39 0.6×	18	344
A Koch Germany	8	180 0.6×	80 0.6×	77 0.8×	96 1.5×	101 1.6×	11	339
Özge Alper United States	9	200 0.7×	180 1.3×	38 0.4×	41 0.6×	25 0.4×	12	365
Cláudia Miranda Italy	11	223 0.7×	143 1.0×	72 0.8×	52 0.8×	35 0.6×	15	411
J Sandle United Kingdom	11	146 0.5×	182 1.3×	40 0.4×	58 0.9×	43 0.7×	15	382

Countries citing papers authored by Suzanne R.L. Young

Since Specialization

Citations

This map shows the geographic impact of Suzanne R.L. Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne R.L. Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne R.L. Young more than expected).

Fields of papers citing papers by Suzanne R.L. Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne R.L. Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne R.L. Young. The network helps show where Suzanne R.L. Young may publish in the future.

Co-authorship network of co-authors of Suzanne R.L. Young

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne R.L. Young. A scholar is included among the top collaborators of Suzanne R.L. Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne R.L. Young. Suzanne R.L. Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Curigliano, Giuseppe, Joyce O’Shaughnessy, François‐Clément Bidard, et al.. (2025). Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.. Journal of Clinical Oncology. 43(16_suppl). 1001–1001. 2 indexed citations

Jhaveri, Komal, Joyce O’Shaughnessy, Fabrice André, et al.. (2023). Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET. Cancer Research. 83(5_Supplement). OT1–1. 6 indexed citations

Konstantinopoulos, Panagiotis A., Jungmin Lee, Bo Gao, et al.. (2022). A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecologic Oncology. 167(2). 213–225. 42 indexed citations

Jhaveri, Komal, Nadia Harbeck, Philippe Aftimos, et al.. (2022). Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator’s choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Cancer Research. 82(4_Supplement). OT2–11. 12 indexed citations

Lim, Elgene, M. Beeram, Amy Prawira, et al.. (2021). Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer. Cancer Research. 81(4_Supplement). OT–9. 3 indexed citations

Jhaveri, Komal, Elgene Lim, Erika Hamilton, et al.. (2021). A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.. Journal of Clinical Oncology. 39(15_suppl). 1050–1050. 22 indexed citations

Hurvitz, Sara A., Miguel Martín, Sameera R. Wijayawardana, et al.. (2019). Abstract P3-10-08: Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer. Cancer Research. 79(4_Supplement). P3–10. 2 indexed citations

Hurvitz, SA, Miguel Martín, Michael F. Press, et al.. (2019). Abstract PD2-10: Treatment with abemaciclib modulates the immune response in gene expression analysis of the neoMONARCH neoadjuvant study of abemaciclib in postmenopausal women with HR+, HER2 negative breast cancer. Cancer Research. 79(4_Supplement). PD2–10. 5 indexed citations

Tolaney, Sara M., Peter Kabos, Maura N. Dickler, et al.. (2018). Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. Journal of Clinical Oncology. 36(15_suppl). 1059–1059. 35 indexed citations

10.

Rugo, HS, Peter Kabos, Ian C. P. Smith, et al.. (2018). Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Cancer Research. 78(4_Supplement). P1–9. 14 indexed citations

11.

Young, Suzanne R.L., et al.. (2013). Focal adhesion kinase is important for fluid shear stress-induced mechanotransduction in osteoblasts. Journal of Bone and Mineral Research. 28(11). 2431–2431.

12.

Young, Suzanne R.L., et al.. (2011). Non-Overlapping Functions for Pyk2 and FAK in Osteoblasts during Fluid Shear Stress-Induced Mechanotransduction. PLoS ONE. 6(1). e16026–e16026. 24 indexed citations

13.

Bidwell, Joseph P., et al.. (2010). Nmp4/CIZ inhibits mechanically induced β‐catenin signaling activity in osteoblasts. Journal of Cellular Physiology. 223(2). 435–441. 19 indexed citations

14.

Young, Suzanne R.L., Rita Gerard-O’Riley, Maureen A. Harrington, & Fredrick M. Pavalko. (2010). Activation of NF-κB by fluid shear stress, but not TNF-α, requires focal adhesion kinase in osteoblasts. Bone. 47(1). 74–82. 33 indexed citations

15.

Hum, Julia M., Suzanne R.L. Young, Rita Gerard-O’Riley, & Fredrick M. Pavalko. (2010). Mechanical Regulation of Wnt/β-catenin Signaling in Bone Cells. IUScholarWorks (Indiana University). 1 indexed citations

16.

Wang, Haifang, Suzanne R.L. Young, Rita Gerard-O’Riley, et al.. (2010). Blockade of TNFR1 signaling: A role of oscillatory fluid shear stress in osteoblasts. Journal of Cellular Physiology. 226(4). 1044–1051. 13 indexed citations

17.

Young, Suzanne R.L. & David G. Skalnik. (2007). CXXC Finger Protein 1 Is Required for Normal Proliferation and Differentiation of The PLB-985 Myeloid Cell Line. DNA and Cell Biology. 26(2). 80–90. 17 indexed citations

18.

Young, Suzanne R.L., Christen L. Mumaw, James A. Marrs, & David G. Skalnik. (2006). Antisense Targeting of CXXC Finger Protein 1 Inhibits Genomic Cytosine Methylation and Primitive Hematopoiesis in Zebrafish. Journal of Biological Chemistry. 281(48). 37034–37044. 20 indexed citations

19.

Balch, Curtis, Pearlly S. Yan, Teresa Craft, et al.. (2005). Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Molecular Cancer Therapeutics. 4(10). 1505–1514. 110 indexed citations

20.

Carlone, Diana L., et al.. (2005). Reduced Genomic Cytosine Methylation and Defective Cellular Differentiation in Embryonic Stem Cells Lacking CpG Binding Protein. Molecular and Cellular Biology. 25(12). 4881–4891. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact